GRAIL (NASDAQ:GRAL) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

Key Points

• RBC raised its GRAIL price target to $100 from $84 but maintained a Sector Perform rating; the target implies 16.2% downside from the prior close.
• GRAIL reported quarterly EPS of ($2.21), better than estimates, but revenue of $37.5 million missed forecasts of $44.2 million. Shares fell $24.32 to $119.34 in Thursday trading.
• An FDA advisory committee backed approval of GRAIL’s Galleri cancer-screening test, with a final FDA decision expected in early 2027. Test volume grew about 24% year over year, though price cuts to encourage adoption could pressure revenue and margins.

GRAIL (NASDAQ:GRAL - Get Free Report) had its price objective upped by Royal Bank Of Canada from $84.00 to $100.00 in a research report issued on Thursday, Benzinga reports. The brokerage currently has a "sector perform" rating on the stock. Royal Bank Of Canada's price target would indicate a potential downside of 16.20% from the stock's previous close.

GRAL has been the topic of a number of other reports. Wall Street Zen upgraded GRAIL from a "sell" rating to a "hold" rating in a report on Sunday, September 13th. Weiss Ratings restated a "sell (d-)" rating on shares of GRAIL in a report on Thursday, October 15th. Robert W. Baird lifted their target price on GRAIL from $96.00 to $118.00 and gave the company an "outperform" rating in a research report on Tuesday, September 22nd. Morgan Stanley upped their target price on GRAIL from $60.00 to $120.00 and gave the stock an "equal weight" rating in a report on Monday, October 12th. Finally, Mizuho increased their price target on GRAIL from $65.00 to $100.00 and gave the company a "neutral" rating in a research report on Friday, September 25th. Five analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $121.40.

GRAIL Stock Performance

GRAL traded down $24.32 during midday trading on Thursday, reaching $119.34. 1,407,085 shares of the company were exchanged, compared to its average volume of 976,080. The stock has a market capitalization of $5.33 billion, a P/E ratio of -12.16 and a beta of 2.86. GRAIL has a one year low of $41.50 and a one year high of $166.48. The stock's 50-day simple moving average is $115.58 and its 200 day simple moving average is $79.12.

GRAIL (NASDAQ:GRAL - Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported ($2.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.45) by $0.24. The firm had revenue of $37.53 million during the quarter, compared to analysts' expectations of $44.21 million. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%. On average, research analysts anticipate that GRAIL will post -10.07 earnings per share for the current year.

Insider Transactions at GRAIL

In other news, insider Andrew Partridge sold 7,873 shares of the company's stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $146.39, for a total value of $1,152,528.47. Following the sale, the insider directly owned 155,865 shares of the company's stock, valued at approximately $22,817,077.35. This represents a 4.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Joshua Ofman sold 61,452 shares of the firm's stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $97.74, for a total transaction of $6,006,318.48. Following the completion of the sale, the chief executive officer owned 362,271 shares of the company's stock, valued at $35,408,367.54. This trade represents a 14.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 129,944 shares of company stock worth $14,832,805 in the last ninety days. Insiders own 1.83% of the company's stock.

Institutional Trading of GRAIL

Hedge funds have recently made changes to their positions in the business. Fifth Third Bancorp lifted its holdings in shares of GRAIL by 15,733.3% in the first quarter. Fifth Third Bancorp now owns 475 shares of the company's stock worth $25,000 after acquiring an additional 472 shares during the last quarter. Geneos Wealth Management Inc. boosted its stake in shares of GRAIL by 160.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 585 shares of the company's stock valued at $30,000 after purchasing an additional 360 shares in the last quarter. Allworth Financial LP bought a new stake in shares of GRAIL during the 2nd quarter valued at approximately $35,000. North Star Investment Management Corp. grew its holdings in shares of GRAIL by 809.1% during the 3rd quarter. North Star Investment Management Corp. now owns 300 shares of the company's stock valued at $42,000 after purchasing an additional 267 shares during the last quarter. Finally, Root Financial Partners LLC acquired a new position in GRAIL during the 3rd quarter worth approximately $44,000.

Key Headlines Impacting GRAIL

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: An FDA advisory committee voted in favor of approving GRAIL’s Galleri multi-cancer early detection test. The vote is supportive, though the FDA’s final decision is still pending; management expects a decision in early 2027. GRAIL Q3 results and FDA update
• Positive Sentiment: Galleri test volume rose about 24% year over year to more than 56,000 in the quarter, while revenue increased 14% to $37.3 million. These figures show continued commercial growth. GRAIL Q3 results
• Neutral Sentiment: GRAIL’s adjusted quarterly loss per share was narrower than analysts expected. RBC also raised its price target to $100 from $84 but kept its Sector Perform rating, signaling a measured view of the shares. RBC price target update
• Negative Sentiment: Quarterly revenue of about $37.5 million fell short of the roughly $44.2 million analyst estimate, disappointing investors despite the EPS beat. The miss has been associated with pressure on the stock. GRAIL revenue miss coverage
• Negative Sentiment: GRAIL is cutting Galleri prices to encourage adoption ahead of the FDA decision. The strategy could support test volumes, but may weigh on revenue growth and margins as the company works to scale sales. GRAIL earnings call takeaways

About GRAIL

GRAIL, Inc NASDAQ: GRAL is a healthcare company focused on developing blood-based screening technologies for the early detection of cancer. Its principal product is Galleri, a multi-cancer early detection test designed to identify DNA patterns associated with multiple types of cancer from a single blood sample.

Galleri is intended for use alongside recommended cancer screenings and is available by prescription through qualified healthcare providers in the United States. The test is offered as a laboratory-developed test and has not been approved or cleared by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.